Results 61 to 70 of about 5,204,838 (351)

Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer

Radiation Oncology, 2018
Background Two prospective phase II trials were designed to assess the efficacy and safety of image-guided proton therapy (IGPT) for either medically inoperable or operable stage I non-small cell lung cancer (NSCLC). The present study reports the interim
Koichiro Nakajima, Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Shingo Hashimoto, Toshiyuki Toshito, Kensuke Hayashi, Kenji Akita, Fumiya Baba, Katsumi Nakamae, Jun-etsu Mizoe, Yuta Shibamoto   +11 more
doaj   +1 more source

Proton therapy for brain tumours in the area of evidence-based medicine.

British Journal of Radiology, 2020
ADVANCES IN KNOWLEDGE This review details the indication of brain tumors for proton therapy and give a list of the open prospective trials for these challenging tumors.
D. Weber, P. Lim, S. Tran, M. Walser, A. Bolsi, U. Kliebsch, J. Beer, B. Bachtiary, T. Lomax, A. Pica   +9 more
semanticscholar   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study

Journal of Ovarian Research
Background Previous studies have demonstrated the benefit of radiation therapy for patients with recurrent epithelial ovarian cancer; however, the effects of proton beam therapy in these patients remain unelucidated.
Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Masanori Machida, Yuntao Dai, Yusuke Azami, Ichiro Seto, Kanako Takayama, Motohisa Suzuki, Tatsuhiko Nakasato, Yasuhiro Kikuchi, Takahiro Kato, Akiko Yamaguchi, Shu Soeda, Keiya Fujimori, Masao Murakami   +15 more
doaj   +1 more source

Proton therapy delivery: What is needed in the next ten years?

British Journal of Radiology, 2020
Proton radiation therapy has been used clinically since 1952, and major advancements in the last 10 years have helped establish protons as a major clinical modality in the cancer-fighting arsenal.
A. Schreuder, J. Shamblin
semanticscholar   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Fast, Automated, Knowledge-Based Treatment Planning for Selecting Patients for Proton Therapy Based on Normal Tissue Complication Probabilities [PDF]

, 2022
Roni Hytönen, Marije R. Vergeer, Reynald Vanderstraeten, Timo Koponen, C. Smith, Wilko F.A.R. Verbakel   +5 more
openalex   +1 more source

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Journal of Clinical Oncology, 2018
Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non-small-cell lung cancer (NSCLC).
Z. Liao, J. J. Lee, R. Komaki, Daniel R. Gomez, Michael S. O’Reilly, F. Fossella, G. Blumenschein, J. Heymach, A. Vaporciyan, S. Swisher, P. Allen, Noah Chan Choi, Thomas F. DeLaney, Stephen M. Hahn, James D. Cox, Charles S. Lu, R. Mohan   +16 more
semanticscholar   +1 more source

Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base

International Journal of Particle Therapy, 2020
Purpose: To demonstrate temporal lobe necrosis (TLN) rate and clinical/dose-volume factors associated with TLN in radiation-naïve patients with head and neck cancer treated with proton therapy where the field of radiation involved the skull base ...
S. Kitpanit, Anna Lee, K. Pitter, D. Fan, J. Chow, B. Neal, Zhiqiang Han, P. Fox, K. Sine, D. Mah, L. Dunn, E. Sherman, L. Michel, I. Ganly, R. Wong, J. Boyle, Marc A. Cohen, Bhuvanesh Singh, C. Brennan, I. Gavrilovic, V. Hatzoglou, B. O'Malley, K. Zakeri, Yao Yu, Linda C. Chen, D. Gelblum, J. Kang, S. McBride, C. J. Tsai, N. Riaz, N. Lee   +30 more
semanticscholar   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source